Belluscura has developed the X-PLOR, a lightweight, portable oxygen delivery device aimed at treating the millions of people globally suffering from chronic lung diseases. The company plans to launch this novel and cost-effective device in the US in 2019, with Europe to follow.
Over 250 million people suffer from Chronic Obstructive Pulmonary Disease (COPD) globally; now the third leading cause of death. COPD is not curable, but patients with COPD are prescribed supplemental oxygen to help relieve shortness of breath and reduce the risk of death. Improving both the mobility of patients and their quality of life is key to living longer, more productive lives.
We have an exclusive license to a patented portable oxygen concentrator (POC), the X-PLOR, that delivers 96% pure oxygen to patients 24/7. The X-PLOR is designed to replace metal oxygen tanks and heavier devices.
Weighing only 1.4kg, X-PLOR is 33% lighter and our research suggests can provide 37% more oxygen per kg than leading competitors. X-PLOR will be both portable, increasing the mobility of people suffering from COPD and price efficient, costing less than tanks over the duration of the disease.
As pollution, smoking and lives increase, the oxygen market will continue to grow from £1.1bn to £1.9bn by 2024. Our research suggests that a 3% market share within 3 years could generate £46m in sales.
We plan to expand our proprietary oxygen platform technology into other multi £bn markets such as sleep and wound care. Moreover, we have filed patents on a next-generation portable artificial lung.
We are seeking to raise £500,000 to complete regulatory clearance and launch the X-PLOR in September 2019.